A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorAvistone Biotechnology Co., Ltd.
About this trial
This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-2
Life expectancy ≥ 12 weeks
Measurable disease per RECIST v1.1
Disqualifiers
Active infection including tuberculosis and HBV, HCV or HIV
Known active or untreated CNS metastases
Participants with carcinomatous meningitis or meningeal metastases, or spinal cord compression
Participants with serious cardiovascular or cerebrovascular diseases
Trial design
Treatments tested in this trial
- ANS03
Treatment groups
96 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov